Suven Life Sciences Approves Preferential Allotment of Equity Shares

Suven Life Sciences Ltd announced the outcome of its Board Meeting held on July 08, 2026. The board approved the allotment of 1,85,70,133 equity shares on a preferential basis upon conversion of fully paid warrants at an issue price of Rs. 134/- per share. The company received 100% consideration amounting to Rs. 248,83,97,822/-. Consequently, the paid-up equity share capital has increased. Additionally, the board approved the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second term and the incorporation of a wholly-owned subsidiary in Singapore.